Tofacitinib °æ±¸Á¦(Ç°¸í: Á©ÀÜÁîÁ¤ 5¹Ð¸®±×·¥ µî) ¡á °í½Ã °³Á¤ Àüü³»¿ë 1. °¢ ¾àÁ¦º° Çã°¡»çÇ× ¹üÀ§ ³»¿¡¼ ¾Æ·¡¿Í °°Àº ±âÁØÀ¸·Î Åõ¿© ½Ã ¿ä¾ç±Þ¿©¸¦ ÀÎÁ¤Çϸç, µ¿ ÀÎÁ¤±âÁØ ÀÌ¿Ü¿¡´Â ¾à°ª Àü¾×À» ȯÀÚ°¡ ºÎ´ãÅä·Ï ÇÔ. - ¾Æ ·¡ - °¡. ¼ºÀÎÀÇ È°µ¿¼º ¹× ÁøÇ༺ ·ù¸¶Æ¼½º°üÀý¿° 1) Åõ¿©´ë»ó ACR/EULAR Áø´Ü±âÁØ(2010³â Á¦Á¤)¿¡ ºÎÇÕÇÏ´Â ¼ºÀÎ ·ù¸¶Æ¼½º °üÀý¿° ȯÀÚ Áß ´ÙÀ½ ÇÑ °¡Áö¿¡ ÇØ´çÇÏ°í µÎ °¡Áö Á¾·ù ÀÌ»ó(MTX(methotrexate) Æ÷ÇÔ)ÀÇ DMARDs(Diease Modifying AntiRheumatic Drugs)·Î 6°³¿ù ÀÌ»ó(°¢ 3°³¿ù ÀÌ»ó) Ä¡·áÇÏ¿´À¸³ª, Ä¡·áÈ¿°ú°¡ ¹ÌÈíÇϰųª »ó±â ¾àÁ¦µéÀÇ ºÎÀÛ¿ë µîÀ¸·Î Ä¡·á¸¦ Áß´ÜÇÑ È¯ÀÚ (´Ù¸¸, MTX »ç¿ëÀÌ ºÒ°¡´ÉÇÑ, °£Áúȯ ¶Ç´Â ½ÅºÎÀü µîÀÇ °æ¿ì¿¡´Â MTX¸¦ Á¦¿ÜÇÑ µÎ Á¾·ù ÀÌ»óÀÇ DMARDs »ç¿ë) - ´Ù À½ - °¡) DAS28ÀÌ 5.1 ÃÊ°ú ³ª) DAS28ÀÌ 3.2 ¡ 5.1ÀÌ°í ¿µ»ó °Ë»ç »ó °üÀý ¼Õ»óÀÇ ÁøÇàÀÌ ÀÖ´Â °æ¿ì ¡Ø DAS28(Disease Activity Score in 28 joints) £¿ DAS28(ESR) = 0.56¡¿¡î(TJC-28) + 0.28¡¿¡î(SJC-28) + 0.014¡¿VAS + 0.70¡¿ln(ESR) £¿ DAS28(CRP) = 0.56¡¿¡î(TJC-28) + 0.28¡¿¡î(SJC-28) + 0.014¡¿VAS + 0.36¡¿ln(CRP+1) + 0.96 TJC: ¾ÐÅë °üÀý¼ö SJC: ºÎÁ¾ °üÀý¼ö VAS: ȯÀÚÀÇ Àü¹ÝÀûÀÎ »óź¸°í 2) Æò°¡¹æ¹ý °¡) µ¿ ¾àÁ¦¸¦ 6°³¿ù°£ »ç¿ë ÈÄ Æò°¡½Ã DAS28ÀÌ 1.2 ÀÌ»ó °¨¼ÒÇÑ °æ¿ì Ãß°¡ 6°³¿ù°£ÀÇ »ç¿ëÀ» ÀÎÁ¤ÇÔ. ³ª) ÀÌÈÄ¿¡´Â 6°³¿ù¸¶´Ù Æò°¡¸¦ ÇÏ¿© ù 6°³¿ù°ÀÇ Æò°¡ °á°ú°¡ À¯ÁöµÇ¸é Áö¼ÓÀûÀÎ Åõ¿©¸¦ ÀÎÁ¤ÇÔ.
³ª. ¼ºÀÎÀÇ Áߵ-ÁßÁõ È°µ¿¼º ±Ë¾ç¼º ´ëÀå¿° 1) Åõ¿©´ë»ó Corticosteroid³ª 6-Mercaptopurine ¶Ç´Â Azathioprine µî º¸ÆíÀûÀÎ Ä¡·á ¾àÁ¦¿¡ ´ëÇØ ÀûÁ¤ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê°Å³ª ³»¾à¼ºÀÌ ¾ø´Â °æ¿ì ¶Ç´Â »ó±â ¾àÁ¦°¡ ±Ý±âÀÎ Áߵ-ÁßÁõÀÇ ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ ¡Ø Áߵ-ÁßÁõÀÇ ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ ¡Ø ±Ë¾ç¼º´ëÀå¿° È°µ¿Æò°¡¸¦ À§ÇÑ ¸ÞÀÌ¿ä Á¡¼ö½Ã½ºÅÛ(Mayo Scoring System for Assessment of Ulcerative Colitis Activity) ¹èº¯ºóµµ(Stool frequency) 0 = Normal no. of stools for this patient 1 = 1 to 2 stools more than normal 2 = 3 to 4 stools more than normal 3 = 5 or more stools more than normal Subscore, 0 to 3 Á÷ÀåÃâÇ÷(Rectal bleeding) 0 = No blood seen 1 = Streaks of blood with stool less than half the time 2 = Obvious blood with stool most of the time 3 = Blood alone passes Subscore, 0 to 3 ³»½Ã°æ °á°ú(Findings on endoscopy) 0 = Normal or inactive disease 1 = Mild disease (erythema, decreased vascular pattern, mild friability) 2 = Moderate disease (Marked erythema, lack of vascular pattern, friability, erosions) 3 = Severe disease (Spontaneous bleeding, ulceration) Subscore, 0 to 3 ÀÇ»çÀÇ Á¾ÇÕÆò°¡(Physician¡¯s global assessment) 0 = Normal 1 = Mild disease 2 = Moderate disease 3 = Severe disease Subscore, 0 to 3 : ¾Æ·¡ÀÇ Á¡¼ö¸¦ ÇÕ»êÇÏ¿© Áߵ-ÁßÁõ ±Ë¾ç¼º ´ëÀå¿° ¿©ºÎ¸¦ ÆÇÁ¤(Mayo score 6 to 12 and Endoscopy subscore ¡Ã 2) 2) Æò°¡¹æ¹ý µ¿ ¾àÁ¦¸¦ 16ÁÖ µ¿¾È Åõ¾à ÈÄ Æò°¡ÇÏ¿© ´ÙÀ½ °¢ È£ÀÇ Á¶°ÇÀ» ¸ðµÎ ÃæÁ·ÇÏ´Â °æ¿ì Áö¼ÓÀûÀÎ Åõ¿©¸¦ ÀÎÁ¤ÇÔ. - ´Ù À½ - °¡) Mayo score°¡ ÃÖÃÊ Åõ¿©½ÃÁ¡ º¸´Ù 30% ÀÌ»ó °¨¼ÒÇÏ°í 3Á¡ ÀÌ»ó °¨¼ÒÇÑ °æ¿ì ³ª) Rectal bleeding subscore 1Á¡ ÀÌ»ó °¨¼Ò ¶Ç´Â Rectal bleeding subscore 0Á¡ ¶Ç´Â 1Á¡ÀÎ °æ¿ì 2. Á¾¾ç±«»çÀÎÀÚ¾ËÆÄÀúÇØÁ¦(TNF-¥á inhibitor: Adalimumab, Etanercept, Golimumab, Infliximab ÁÖ»çÁ¦) ¶Ç´Â Abatacept, Tocilizumab, Ustekinumab, Vedolizumab ÁÖ»çÁ¦¿¡ È¿°ú°¡ ¾ø°Å³ª ºÎÀÛ¿ëÀ¸·Î Åõ¾àÀ» Áö¼ÓÇÒ ¼ö ¾ø´Â °æ¿ì ¶Ç´Â º¹¾à¼øÀÀµµ °³¼±ÀÇ Çʿ伺ÀÌ ÀÖ´Â °æ¿ì(±³Ã¼ÇÑ ¾àÁ¦´Â ÃÖ¼Ò 6°³¿ù Åõ¿©¸¦ À¯ÁöÇϵµ·Ï ±Ç°íÇÔ)¿¡ µ¿ ¾àÁ¦·Î ±³Ã¼Åõ¿©(Switch)¸¦ ±Þ¿©·Î ÀÎÁ¤Çϸç, ÀÌ °æ¿ì¿¡´Â ±³Ã¼Åõ¿©¿¡ ´ëÇÑ Åõ¿©¼Ò°ß¼¸¦ ÷ºÎÇÏ¿©¾ß ÇÔ. 3. Àå±âó¹æ ½Ã 1ȸ ó¹æ±â°£Àº Åð¿øÇÒ °æ¿ì ¹× ¿Ü·¡ÀÇ °æ¿ì¿¡´Â ÃÖ´ë 30ÀϺбîÁö·Î ÇÔ. ´Ù¸¸, ÃÖÃÊ Åõ¾àÀϷκÎÅÍ 24ÁÖ ÀÌÈÄ¿¡ ¾ÈÁ¤µÈ Áúº´È°µ¿µµ¸¦ º¸ÀÌ°í ºÎÀÛ¿ëÀÌ ¾ø´Â ȯÀÚÀÇ °æ¿ì ÃÖ´ë 60¡90ÀϺбîÁö ÀÎÁ¤ÇÔ. 4. µ¿ ¾àÁ¦ÀÇ Çã°¡»çÇ× Áß ¡®»ç¿ë »ó ÁÖÀÇ»çÇ×(±Ý±â µî)¡¯À» ¹Ýµå½Ã Âü°íÇÏ¿© Åõ¿©ÇÏ¿©¾ß ÇÔ. 5. µ¿ ¾àÁ¦¸¦ »ç¿ëÇÏ´Â °æ¿ì¿¡´Â¡¸TNF-¥á inhibitor »ç¿ë ½Ã Àẹ°áÇÙ Ä¡·áÁöħ¡¹À» µû¶ó¾ß ÇÔ. ¡á °í½Ã °³Á¤ °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ) °í½Ã Á¦2021-101È£(2021.4.1.) ¡á °í½Ã °³Á¤ »çÀ¯ ¡®Á©ÀÜÁîXR¼¹æÁ¤11¹Ð¸®±×·¥¡¯ÀÌ ½Å±Ô µîÀç ¿¹Á¤ÀÓ¿¡ µû¶ó, µ¿ °í½Ã¿¡ µû¶ó ÀÎÁ¤Ç쵂 Á©ÀÜÁîÁ¤5¹Ð¸®±×·¥, Á©ÀÜÁîÁ¤10¹Ð¸®±×·¥(±âµîÀçÇ°¸ñ)ÀÇ Çã°¡ ÀûÀÀÁõÀÌ ´Ù¸¥ Á¡À» °í·Á °¢ ¾àÁ¦º° Çã°¡»çÇ׿¡ µû¸¥´Ù´Â »çÇ×À» ¸í½Ã ¡á °ü·Ã¹®Çå µî ¡¤ ½ÄÇ°ÀǾàÇ°¾ÈÀüó Çã°¡»çÇ× ¡á º¯°æ Àü °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ) °í½Ã Á¦2020-305È£(2021.1.1.) Ãâó : °Ç°º¸Çè½É»çÆò°¡¿ø |